Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ABCF2 , an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells

23 Jan 2017

Abstract excerpt

Previously, we have demonstrated that NRF2 plays a key role in mediating cisplatin resistance in ovarian cancer. To further explore the mechanism underlying NRF2-dependent cisplatin resistance, we stably overexpressed or knocked down NRF2 in parental and cisplatin-resistant human ovarian cancer cells, respectively. These two pairs of stable cell lines were then subjected to microarray analysis, where we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Genomics, phytochemicals, and oxidative stress
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28112439
DOI: 10.1002/mc.22615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ABCF2 , an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cellsPMID 28112439Read ↗

Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatinSemantic proximity Read ↗

Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancerSemantic proximity Read ↗

Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters.Semantic proximity Read ↗

Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.Semantic proximity Read ↗

E2F1 drives chemotherapeutic drug resistance via ABCG2Semantic proximity Read ↗

Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer.Semantic proximity Read ↗

Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.Semantic proximity Read ↗

Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer PatientsSemantic proximity Read ↗

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib TreatmentsSemantic proximity Read ↗

[Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations].Semantic proximity Read ↗

The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cellsSemantic proximity Read ↗

Nuclear factor Nrf2 promotes glycosidase OGG1 expression by activating the AKT pathway to enhance leukemia cell resistance to cytarabineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.